Indian Rotavirus Vaccines market size stood at USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Rotaviruses are a common infection in children in India. Disease with rotavirus usually causes stomach upset, vomiting, diarrhea, and sometimes fever. Rotavirus is the most severe and lethal cause of childhood diarrhoea, and is responsible for the death of approximately 100,000 small children in India each year. Diarrhea is responsible for about 9% of under-five deaths globally and 10% of under five deaths in India translating to around 1.2 lakh deaths annually in India. India introduced the oral rotavirus vaccine (ROTAVAC) in 2016, in four states. The study found that the overall rotavirus positivity was 41.7% in the north compared to 33.1% in the south India. Rotavirus disease is highly transmitted disease and spreads very easily among children owing to their poor hygiene. The rotavirus vaccine is a common problem in clinics and hospitals. The increase in incidents is driving the rotavirus vaccine market during the forecast period.
The increasing prevalence of Rotavirus-induced diseases among infants is responsible for the growth of this market. An increase in awareness regarding vaccines among patients can accelerate the growth of this market. The rise in the population of immunity-compromised individuals can act as a catalyst for market growth. An increase in the development and manufacturing of vaccines would enhance the market growth.